Roche, Isis ally to develop Huntington's disease drugs

04/9/2013 | Yahoo

Roche Holding and Isis Pharmaceuticals agreed to collaborate in the development of Huntington's disease drugs using the latter's antisense technology. The partners will initially focus on Isis' lead drug candidate designed to inhibit production of all forms of a protein involved in the genetic brain disorder. Isis will get $30 million upfront and as much as $362 million in licensing and milestone fees plus sales royalties on drugs arising from the collaboration.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY